CBD and THC Creams for Pain: Do They Actually Work?

CBD and THC creams have become an easy sell because the idea is so intuitive. Something hurts, so you rub the treatment directly over the painful area.

The products are now everywhere. They are sold for arthritic hands, aching knees, sore muscles, back pain, joint stiffness, inflammation, and exercise recovery. Some contain CBD alone. Others contain THC, multiple cannabinoids, menthol, camphor, capsaicin, arnica, botanical oils, or several of these ingredients together.

People often report that they feel something after applying them. The difficult part is figuring out what produced the effect.

A cooling sensation may come from menthol. Massage itself can temporarily change how an area feels. A carrier oil may soften irritated skin. A cannabinoid may be contributing as well, but that depends on whether it reaches the relevant tissue in a sufficient concentration.

This is what makes topical cannabinoids scientifically interesting and commercially messy at the same time. The pharmacology is real. The clinical evidence is limited, and products that share the same label can behave very differently once they are applied to human skin.

That makes this a good example of the approach behind Medicine, Not Marketing: understand the mechanism, look at what has actually been demonstrated in people, and resist making the evidence sound stronger than it is.

---

Why the Biology Makes Sense

Human skin has its own active signaling environment. It contains peripheral nerves, keratinocytes, immune cells, hair follicles, sebaceous glands, blood vessels, fibroblasts, and a variety of receptors involved in pain and inflammation.

The endocannabinoid system is part of that environment.

CB1 and CB2 cannabinoid receptors have been identified in cutaneous nerve fibers and several types of epidermal and dermal cells. The skin also produces endogenous cannabinoids, including anandamide and 2-AG, along with enzymes that synthesize and metabolize them.

Cannabinoid signaling is broader than CB1 and CB2. CBD and other cannabinoids can interact with transient receptor potential channels such as TRPV1 and TRPA1, along with PPAR signaling and other molecular pathways involved in sensory perception, immune activity, and inflammation.

There are therefore several plausible ways for a cannabinoid placed on the skin to influence pain signaling. Whether that happens in practice depends on concentration, formulation, penetration, and where the pain is actually coming from.

---

How THC Can Affect Pain Signaling

THC and CBD have very different pharmacology.

THC has substantial activity at CB1 and CB2 cannabinoid receptors. CB1 receptors are found throughout the nervous system, including peripheral sensory pathways. Activating these receptors can alter neuronal excitability and reduce the release of neurotransmitters involved in pain transmission.

CB2 receptors are prominent in immune-related cells and tissues. Their activation can modify inflammatory and immune signaling, which has made peripheral CB2 pathways an attractive area of pain research.

Researchers have long been interested in whether these effects can be produced locally without delivering enough THC to the brain to cause significant psychoactive effects. A topical or transdermal preparation is one possible way to approach that problem.

The presence of a receptor does not guarantee that a cream will work. The formulation still has to deliver enough THC across the skin to reach the receptor in question.

---

CBD Works Differently

CBD does not act like THC as a conventional CB1 agonist. Its effects involve a broader group of molecular targets, which is part of the reason its pharmacology is harder to summarize in one sentence.

TRPV1 is especially relevant to pain research. This ion channel is involved in the detection of heat and painful stimuli and is also activated by capsaicin. Repeated activation can desensitize sensory neurons and reduce their response to subsequent stimulation.

CBD can influence TRPV1 and related TRP channels. It also interacts with PPAR signaling, serotonin pathways, and components of the endogenous cannabinoid system. Laboratory studies have reported changes in inflammatory mediators and immune-cell signaling as well.

These findings provide a reasonable foundation for clinical research, but laboratory anti-inflammatory activity should not be confused with proof that a CBD cream reduces inflammation inside an arthritic knee or an injured muscle.

The distinction is important. Cell studies identify biological possibilities. Clinical trials tell us whether a treatment improves pain, function, swelling, stiffness, or another outcome that matters to a patient.

For more on the larger inflammatory picture, see Inflammation and Longevity Medicine.

---

The Skin Barrier May Be the Biggest Problem

The skin is remarkably good at preventing chemicals from entering the body. The stratum corneum, its outermost layer, is the first major obstacle any topical cannabinoid has to overcome.

CBD and THC are highly lipophilic molecules. They dissolve readily in fats and oils, but that does not mean they automatically move from a cream through the stratum corneum and into deeper tissue.

A useful human study published in 2024 examined five commercially available hemp-derived CBD products: a cream, lotion, patch, balm, and gel. Researchers measured whether CBD from the products could be detected systemically after application.

Only three of the five produced measurable transdermal absorption.

Absorption also varied substantially among the products that did get through. The lotion produced the greatest systemic CBD exposure and contained both a relatively large CBD dose and a permeation enhancer. Some other products contained substantial quantities of CBD yet produced little or no measurable CBD in blood.

The practical implication is simple: the number on the front of the package is only the amount placed into the product. It does not tell you how much crosses the skin.

The carrier matters. Concentration matters. Penetration enhancers matter. So do contact time, application site, skin thickness, and the condition of the skin itself.

A 500-milligram formulation with effective delivery could conceivably produce more tissue exposure than a 2,000-milligram balm that barely penetrates the stratum corneum.

---

Topical and Transdermal Mean Different Things

Consumer products frequently blur these terms, but they describe different treatment strategies.

A topical product is generally intended to act within the skin or nearby superficial tissue. A transdermal formulation is designed to carry an active compound across the skin barrier, potentially reaching deeper tissues or the systemic circulation.

The distinction matters when reading cannabinoid studies.

A simple oil-based balm is not equivalent to a transdermal formulation containing penetration enhancers or specialized delivery technology. Positive results from one formulation cannot automatically be applied to every other product containing the same cannabinoid.

It also means that the common assumption that anything rubbed on the skin stays local is not always correct. Properly designed transdermal cannabinoid products can produce measurable blood concentrations.

How much enters the circulation depends on the formulation and dose.

---

What Do We Know About Arthritis Pain?

One of the better-known clinical trials involved 18 people with symptomatic arthritis at the base of the thumb.

In the randomized, double-blind crossover study, participants used either topical CBD in a shea-butter vehicle or shea butter alone for two weeks, followed by the alternate treatment.

Participants reported greater improvement in pain and disability while using CBD. Grip strength, pinch strength, and range of motion did not improve to the same degree.

It is a worthwhile result because it came from a controlled trial rather than an uncontrolled consumer survey. It is also a very small study involving one joint and one formulation over a short period of time.

It therefore supports the possibility that topical CBD can reduce localized osteoarthritis pain in some patients. It does not establish CBD cream as a general treatment for arthritis of the knees, hips, shoulders, spine, or hands.

The larger evidence remains uncertain. The 2025 AHRQ living systematic review of cannabis and other plant-based treatments for chronic pain concluded that evidence specifically supporting topical CBD was still insufficient.

For more on arthritis itself, see Arthritis Is Not Just Aging: Hormones, Inflammation, and the Biology of Joint Health.

---

CBD Cream for Post-Workout Soreness

Athletic recovery products have become one of the largest markets for topical CBD. Claims commonly include reduced soreness, less inflammation, and faster muscle recovery.

The controlled trials so far have been disappointing.

In one randomized placebo-controlled study, 28 young adults used approximately 100 milligrams of topical CBD after strenuous lower-body exercise. Researchers followed muscle soreness, pain sensitivity, strength, and performance.

CBD did not provide a meaningful advantage over placebo.

A separate randomized crossover pilot study published in 2026 looked at topical CBD gel after exercise-induced muscle damage. Fifteen physically active adults completed a demanding jumping protocol and applied CBD or placebo gel during the following 72 hours. The results again failed to show a convincing improvement in muscle recovery.

These are small studies, and they cannot tell us whether every possible CBD formulation would fail. They do make broad claims about CBD as a proven post-workout recovery treatment difficult to support.

For ordinary delayed-onset muscle soreness, the clinical evidence currently falls well short of the enthusiasm surrounding the products.

---

Neuropathic Pain May Be More Promising

The most interesting recent clinical signal may be coming from neuropathic pain rather than exercise soreness.

A randomized double-blind trial involving 100 adults with painful diabetic peripheral neuropathy compared a standardized transdermal medical-cannabis formulation with placebo for 12 weeks. The active preparation contained THC, CBD, and CBN.

Participants using the cannabinoid formulation experienced substantially greater improvement in neuropathic pain scores.

This is a notable finding, but it does not tell us that CBD alone was responsible. Three cannabinoids were used, and the product was specifically formulated for transdermal medical delivery.

Diabetic neuropathy is also very different from arthritis or a sore muscle after exercise. Neuropathic pain involves abnormal nerve signaling, which may make cannabinoid receptor pathways particularly relevant.

The study is encouraging evidence that properly designed cannabinoid formulations may have a role in localized neuropathic pain. It should not be used as evidence that a retail CBD balm will produce the same result.

---

If the Cream Helps, Which Ingredient Did the Work?

This is an underappreciated problem in the topical cannabinoid market.

Many CBD pain products contain ingredients with established sensory effects of their own. Menthol is common. So are camphor, capsaicin, eucalyptus, wintergreen, arnica, and various essential oils.

Menthol activates temperature-sensitive sensory channels and produces the familiar cooling counterirritant effect. Capsaicin acts through TRPV1 and has a well-established role in topical pain treatment.

A person using a cream that contains CBD, menthol, camphor, and several botanical ingredients may genuinely feel better after applying it. That improvement still does not tell us whether CBD contributed much to the result.

This is why good topical-drug studies use a vehicle control whenever possible. The placebo preparation should resemble the active treatment closely enough that differences in texture, smell, cooling sensation, and application do not give away which product is being used.

---

What Do We Know About THC Creams?

Clinical research on ordinary topical THC products is even more limited than the research on CBD creams.

The pharmacology is plausible. THC has direct activity at cannabinoid receptors involved in peripheral pain signaling, and transdermal research demonstrates that THC can cross human skin when the formulation is engineered to deliver it.

Most of the stronger evidence for THC in chronic pain, however, comes from oral, inhaled, or oromucosal cannabis preparations rather than creams applied to one painful area.

The diabetic-neuropathy trial is important because it shows that a THC-containing formulation can produce a meaningful effect through the skin. It does not establish the effectiveness of ordinary THC lotions.

There is also a practical difference between CBD and THC once systemic absorption becomes significant. A sufficiently absorbed THC product could potentially produce central nervous system effects, including psychoactive effects, depending on the formulation and dose.

Anyone evaluating a topical THC product therefore needs to know considerably more than whether the label says “cannabis cream.”

---

What to Look for in a Cannabinoid Cream

There is not enough clinical evidence for us to describe any retail CBD or THC cream as a proven treatment for arthritis or musculoskeletal pain. Someone who nevertheless wants to try one should at least choose a product that provides useful information about what it contains.

• Look for independent laboratory testing. A current certificate of analysis should identify CBD, THC, and other cannabinoids and provide contaminant testing.
• Calculate the dose rather than relying on the front label. A container that says “2,000 mg CBD” may sound impressive, but the relevant number is closer to the amount applied each time.
• Read the entire active-ingredient list. Menthol, camphor, capsaicin, salicylates, and other ingredients can contribute substantially to the way the product feels.
• Do not assume higher cannabinoid content means better delivery. Penetration depends heavily on the formulation.
• Avoid applying the product to damaged skin unless the product was designed for that use. Broken or irritated skin can alter absorption and increase irritation.
• Check the THC content carefully. Laws and product standards vary, and people who undergo drug testing should be particularly cautious with THC-containing and full-spectrum products.

Quality control remains another issue. Cannabinoid content in retail products has not always matched label claims, and contamination with THC or other compounds can occur. That makes independent testing more important than branding.

---

What the Evidence Supports Right Now

Topical cannabinoids are not an implausible treatment dressed up in cannabis marketing. The skin contains receptors and sensory pathways that cannabinoids can influence, and human pharmacokinetic research confirms that some formulations can penetrate the skin.

There are also early clinical signals worth taking seriously. Topical CBD improved pain in a small thumb-arthritis trial. A standardized THC/CBD/CBN transdermal preparation performed well in a larger study of painful diabetic neuropathy.

The limits are just as important. Federal evidence reviews still consider topical CBD data insufficient. Exercise-recovery trials have not shown meaningful benefit. Absorption varies widely between formulations, and many commercial cannabinoid creams contain other active ingredients capable of producing analgesic effects on their own.

For now, topical CBD and THC belong in the category of treatments that may help some patients and deserve better research, particularly for localized arthritis and neuropathic pain. They should not be presented as established anti-inflammatory or musculoskeletal therapies.

The formulation is likely to determine much of what happens next in this field. A standardized product with known cannabinoid concentrations and reliable skin delivery is a very different proposition from a jar of hemp balm with an impressive number printed on the label.

Related HormoneSynergy® Resources

---

Selected Research

• Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update. AHRQ.
• Heineman JT, et al. A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. J Hand Surg Am. 2022.
• Pastina JT, et al. Topical Cannabidiol Application May Not Attenuate Muscle Soreness or Improve Performance. Cannabis Cannabinoid Res.
• Topical application of cannabidiol for muscle recovery after exercise-induced muscle damage: a randomized, double-blinded pilot study. J Cannabis Res. 2026.
• Zamarripa CA, et al. Pharmacokinetics and pharmacodynamics of five distinct commercially available hemp-derived topical cannabidiol products. J Anal Toxicol. 2024.
• Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities.

---

FAQ: CBD and THC Creams

Do CBD creams actually work for pain?

There is some evidence of benefit for localized pain, but the research remains limited. One small randomized trial found improvement in thumb osteoarthritis pain with topical CBD, while the 2025 AHRQ evidence review still considered the overall evidence for topical CBD insufficient.

Does CBD cream help sore muscles after exercise?

So far, controlled human trials have not shown a convincing improvement in exercise-induced soreness, strength recovery, or muscle performance.

How could CBD reduce pain through the skin?

CBD can influence sensory ion channels such as TRPV1 along with other pathways involved in nociception, inflammation, and endocannabinoid signaling. Whether those effects become clinically meaningful depends heavily on how much CBD reaches the relevant tissue.

How does topical THC work?

THC activates CB1 and CB2 cannabinoid receptors. Peripheral CB1 signaling can affect sensory nerve activity, while CB2 signaling can modify immune and inflammatory pathways. The formulation still has to deliver enough THC to the tissue for these mechanisms to matter.

Is topical CBD the same as transdermal CBD?

No. Topical products are generally intended to act within the skin or nearby tissue. Transdermal products are specifically formulated to move an active compound through the skin barrier and may produce measurable systemic exposure.

Can CBD actually penetrate human skin?

Yes, but absorption varies widely. Human pharmacokinetic studies have shown that some commercial formulations produce measurable absorption while others do not, even when they contain substantial amounts of CBD.

Do CBD creams reduce inflammation?

CBD has anti-inflammatory effects in laboratory and preclinical studies. Evidence that ordinary commercial CBD creams meaningfully reduce inflammation within human joints or muscles is still limited.

Could menthol be responsible for the relief from a CBD cream?

Yes. Many cannabinoid creams also contain menthol, camphor, capsaicin, or other ingredients with analgesic or counterirritant effects. Improvement after using a combination product does not establish which ingredient produced the benefit.

Can THC creams make someone feel high?

A poorly absorbed topical product may produce little systemic THC exposure, but transdermal formulations can move THC through the skin. With sufficient systemic absorption, psychoactive effects are possible depending on the dose and product.

Are CBD and THC creams proven treatments for arthritis?

No. The available trials are encouraging enough to justify further research, particularly for localized osteoarthritis and neuropathic pain, but topical cannabinoids are not yet established arthritis treatments.